Marta Sarquis1, Stephen J Marx2, Albert Beckers3, Arthur R Bradwell4, William F Simonds5, Maria Aparecida C Bicalho1, Adrian F Daly3, Daniela Betea3, Eitan Friedman6, Luiz De Marco7. 1. Department of Surgery, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av Alfredo Balena 190, Belo Horizonte, 30130-100, Brazil. 2. Section on Genetics and Endocrinology (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD, USA. 3. Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Liège Université, Liège, Belgium. 4. College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 5. Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 6. The Suzanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel. 7. Department of Surgery, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av Alfredo Balena 190, Belo Horizonte, 30130-100, Brazil. Ldemarco@ufmg.br.
Abstract
PURPOSE: Parathyroid cancer is a rare tumor associated with poor prognosis particularly when disseminated. While chemotherapy and/or radiotherapy are of no clinical value in disseminated disease, immunotherapy should be considered. SUBJECT AND RESULTS: A patient with CDC73-associated metastatic parathyroid carcinoma was treated with combined anti-hPTH immunotherapy and surgery. CONCLUSIONS: Following five courses of anti-hPTH immunotherapy and subsequent surgery, a 12-year long remission of disseminated parathyroid cancer is reported. This case further supports the ever-expanding spectrum of cancers that may benefit from immunotherapy.
PURPOSE: Parathyroid cancer is a rare tumor associated with poor prognosis particularly when disseminated. While chemotherapy and/or radiotherapy are of no clinical value in disseminated disease, immunotherapy should be considered. SUBJECT AND RESULTS: A patient with CDC73-associated metastatic parathyroid carcinoma was treated with combined anti-hPTH immunotherapy and surgery. CONCLUSIONS: Following five courses of anti-hPTH immunotherapy and subsequent surgery, a 12-year long remission of disseminated parathyroid cancer is reported. This case further supports the ever-expanding spectrum of cancers that may benefit from immunotherapy.
Authors: Antonio Stefano Salcuni; Filomena Cetani; Vito Guarnieri; Vincenzo Nicastro; Elisabetta Romagnoli; Danilo de Martino; Alfredo Scillitani; David E C Cole Journal: Best Pract Res Clin Endocrinol Metab Date: 2018-12-01 Impact factor: 4.690
Authors: Elliot A Asare; Cord Sturgeon; David J Winchester; Lei Liu; Bryan Palis; Nancy D Perrier; Douglas B Evans; David P Winchester; Tracy S Wang Journal: Ann Surg Oncol Date: 2015-06-16 Impact factor: 5.344
Authors: Etienne Cavalier; Adrian F Daly; Daniela Betea; Pamela Nicoleta Pruteanu-Apetrii; Pierre Delanaye; Phil Stubbs; Arthur R Bradwell; Jean-Paul Chapelle; Albert Beckers Journal: J Clin Endocrinol Metab Date: 2010-06-02 Impact factor: 5.958
Authors: Marta S Sarquis; Leticia G Silveira; Flavio J Pimenta; Eduardo P Dias; Bin T Teh; Eitan Friedman; Ricardo S Gomez; Gabriela C Tavares; Charis Eng; Luiz De Marco Journal: Surgery Date: 2008-03-17 Impact factor: 3.982
Authors: Callisia N Clarke; Panagiotis Katsonis; Teng-Kuei Hsu; Amanda M Koire; Angelica Silva-Figueroa; Ioannis Christakis; Michelle D Williams; Merve Kutahyalioglu; Lily Kwatampora; Yuanxin Xi; Jeffrey E Lee; E Scott Koptez; Naifa L Busaidy; Nancy D Perrier; Olivier Lichtarge Journal: J Endocr Soc Date: 2018-09-03